MAGELLAN-1, Part 2: Glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

Authors
Category Primary study
JournalJournal of Hepatology
Year 2017
This article has no abstract
Epistemonikos ID: 219a16bcc8fa84af7d3d9025a1b1cf8213d74e3b
First added on: Feb 09, 2025